Onkologie. 2009:3(6):351-356

Prostate cancer screening

Kamil Belej
Urologické oddělení Ústřední vojenská nemocnice, Praha

The first attempts for regular prostate cancer screening by digital rectal examination and ultrasonography are dated to 1980s. Later introduction

of the prostate – specific antigen (PSA) blood test casued a revolution in prostate cancer management and almost doubled the risk

of a diagnosis. A decrease or stabilization in prostate cancer death rates has been observed since that time, but has been uncertain whether

there can be a contribution of improved treatment. The recent release of two large randomized trials suggests that if there is a benefit of

screening, it is, at best, small. Article reviews short history of screening for prostate cancer and outlines current knowledge on this issue.

Keywords: prostate cancer, screening, PSA.

Published: January 1, 2010  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Belej K. Prostate cancer screening. Onkologie. 2009;3(6):351-356.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Andriole GL, Crawford ED, Grubb RL 3rd, et al. PLCO Project Team. Mortality results from a randomized prostate-cancer screening trial. N Engl J Med 2009; 360(13): 1310-1319. Go to original source... Go to PubMed...
    2. Auvinen A, Määttänen L, Stenman U-H, et al. Lead-time in prostate cancer screening (Finland). Cancer Causes Control 2002; 13: 279-285. Go to original source... Go to PubMed...
    3. Bangma CH, Roemeling S, Schröder FH. Overdiagnosis and overtreatment of early detected prostate cancer. World J Urol 2007; 25(1): 3-9. Go to original source... Go to PubMed...
    4. Belej K. Transrektální biopsie prostaty v diagnostice karcinomu prostaty. Urol pro praxi 2009; 1: 7-10.
    5. Catalona WJ, Smith DS, Ratliff TL, Basler JW. Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screening. JAMA 1993; 270(8): 948-954. Go to original source...
    6. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991; 324(17): 1156-1161. Go to original source... Go to PubMed...
    7. Ciatto S, Bonardi R, Mazzotta A, et al. Comparing two modalities of screening for prostate cancer: digital rectal examination and transrectal ultrasonography vs. prostate specific antigen. Tumori 1995; 81: 225-229. Go to original source... Go to PubMed...
    8. Cooner WH, Mosley BR, Rutherford CL Jr, et al. Prostate cancer detection in a clinical urological practice by ultrasonography, digital rectal examination and prostate specific antigen. J Urol 1990; 143(6): 1146-1152. Go to original source... Go to PubMed...
    9. Draisma G, Boer R, Otto SJ, et al. Lead times and overdetection due to prostatespecific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 2003; 95: 868-878. Go to original source... Go to PubMed...
    10. Chodak GW, Keller P, Schoenberg HW. Assessment of screening for prostate cancer using the digital rectal examination. J Urol 1989; 141(5): 1136-1138. Go to original source... Go to PubMed...
    11. Kawachi MH and Panel Members. Prostate Cancer Early Detection Guidelines. NCCN Practice Guidenlines in Oncology - v.2.2010. http://www.nccn.org/professionals/physician_gls/PDF/prostate_detection.pdf.
    12. Kolombo I, Poršová M, Zemanová I, a kol. Prostatický specifický antigen (PSA) a digitální rektální vyšetření (DRE) v diagnostice karcinomu prostaty. Urol pro praxi 2008; 9(2): 83-88.
    13. Nijs HTG, Tordoir DMR, Schuurman JH, et al. Randomised trials of prostate cancer screening in the Netherlands: assessment of acceptance and motives for attendance. J Med Screening 1997; 4: 102-106. Go to original source... Go to PubMed...
    14. Pound CR, Partin AW, Eisenberger MA, et al. Natural history of progression after PSA elevation following radical prostatectomy. JAMA 1999; 281(17): 1591-1597. Go to original source... Go to PubMed...
    15. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials 2000; 21(Suppl): 273-309. Go to original source... Go to PubMed...
    16. Schröder FH, Damhuis RA, Kirkels WJ, et al. European randomized study of screening for prostate cancer - the Rotterdam pilot studies. Int J Cancer 1996; 65: 145-151. Go to original source...
    17. Schröder FH, Denis LJ, Roobol M, et al. The story of the European Randomized Study of Screening for Prostate Cancer. BJU Int 2003; 92(Suppl 2): 1-13. Go to original source... Go to PubMed...
    18. Schröder FH, Hugosson J, Roobol MJ, et al. Screening and prostate-cancer mortality in a randomized European study. N Engl J Med 2009; 360(13): 1320-1328. Go to original source... Go to PubMed...
    19. Schröder FH, Roobol MJ, Damhuis RA, et al. Rotterdam randomized pilot studies of screening for prostate cancer-an overview after 10 years. J Natl Cancer Inst. 2005; 97(9): 696. Go to original source... Go to PubMed...
    20. Stamey TA. Making the most out of six systematic sextant biopsies. Urology 1995; 45(1): 2-12. Go to original source... Go to PubMed...
    21. Steyerberg EW, Roobol MJ, Kattan MW, et al. Prediction of indolent prostate cancer: validation and updating of a prognostic nomogram. J Urol 2007; 177: 107-112. Go to original source... Go to PubMed...
    22. Thompson IM, Ernst JJ, Gangai MP, Spence CR. Adenocarcinoma of the prostate: results of routine urological screening. J Urol 1984; 132(4): 690-692. Go to original source... Go to PubMed...
    23. Thompson IM, Pauler DK, Goodman PJ, et al. Prevalence of prostate cancer among men with a prostate-specific antigen level <= 4.0 ng per milliliter. N Engl J Med 2004; 350: 2239-2246. Go to original source... Go to PubMed...
    24. Young HH. Early diagnosis and radical cure of carcinoma of the prostate. Bull Johns Hopkins Hosp 1905; 16: 314-321.

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.